International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Andrew

Blauvelt

,

MD, MBA

Investigator
Oregon Medical Research Center
Portland
,
Oregon
,
United States
IPC Board Member
Dr. Andrew Blauvelt is an Investigator at Oregon Medical Research Center (OMRC), a small business dedicated to performing high-quality clinical research studies in dermatology. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and cellular immunology under Dr. Steve Katz’s direction at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland Veteran’s Affairs (VA) Medical Center (Chief), as well as being Owner and President of OMRC from 2013-2022. Dr. Blauvelt has extensive experience in basic and clinical research related to psoriasis. Within psoriasis immunology research, his laboratory published critical papers on the role of IL-23/Th17 biology in this disease. In the clinic, he founded and ran OHSU’s Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA), one of the first clinics in the country to focus on the multidisciplinary care of patients with psoriasis. In recent years, he has been the international lead/senior investigator on several important clinical trials in psoriasis, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, and POETYK PSO-1. Dr. Blauvelt has published over 360 papers and spoken worldwide on all aspects of psoriasis. In 2021 and 2022, he made the lists of Highly Cited Researchers, representing the top 1% of cited scientists worldwide. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council (IPC), and the International Eczema Council (IEC). In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation (NPF), an organization he has worked with for over 20 years in various capacities.
Last Updated:
01/09/2024

Areas of Interest

Immunology, clinical trials, biologics.

IPC Committees / Groups

Board Member, Disease Severity Working Group, Finance Committee

Languages Spoken

English

Involvement with Other Organization(s)

Have worked with the National Psoriasis Foundation (NPF) for many years in a variety of capacities; currently Chair of NPF’s Medical Board.